Clinical trial
Nitrocamptothecin in Treating Patients With Metastatic Melanoma
NCT00005875 · Astex Pharmaceuticals, Inc., Industry · Completed
Key facts
| NCT number | NCT00005875 |
|---|---|
| Title | Nitrocamptothecin in Treating Patients With Metastatic Melanoma |
| Official title | Phase II Evaluation of RFS 2000 (9-Nitro-Camptothecin, 9NC) in Metastatic Melanoma |
| Lead sponsor | Astex Pharmaceuticals, Inc., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Melanoma (Skin) |
| Intervention type | Drug |
| Interventions | rubitecan |
| Start date | Jan 1, 1999 |
| Completion | Apr 1, 2004 |
| First posted | Apr 13, 2004 |
| Last update posted | Dec 4, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: